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ABSTRACT
Objectives: The objectives of this study were to provide an outlook of urothelial carcinoma through the immunohistochemical expression patterns of 
octamer-binding transcription factor 4 (OCT4) in high-grade transitional cell carcinoma (TCC) of the urinary bladder. 
Methods: A total number of 60 tissue samples were collected for the study. Patients were divided into two groups according to the pathological 
diagnosis of the bladder tissue, Group A: 30 cases with high-grade TCC of the bladder and Group B: 30 cases with apparently normal bladder tissue. 
Tissue immunohistochemical analysis was applied to investigate the expression patterns of cancer stem cell (CSC) markers OCT4 in bladder samples. 
Results: OCT4 was positive in 80% of specimens of Group A and 3.3% in specimens of Group B. The association between OCT4 marker result and 
certain histopathological features in high-grade group: Positive OCT4 result was found in patients with inflammation and necrosis (90.9%) with a 
significant association (p=0.013). Regarding muscular invasion, we noticed that 87.5% of patients with muscular invasion showed positive OCT4 
marker result with a significant association (p=0.039) between OCT4 marker result and muscular invasion. As well, OCT4 marker was highly sensitive 
and specific (sensitivity=66.7%, specificity=96.7%, and accuracy=76.7%). 
Conclusion: There was a significant expression of CSC OCT4 in high-grade TCC, OCT4 can be considered as a key regulator of tumor progression, 
aggressive behavior, and metastasis.
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INTRODUCTION
Urothelial carcinoma (transitional cell carcinoma [TCC]) of the urinary 
bladder represents 90% of all primary tumors of this organ, and one 
of the most common 10 malignancies in Iraq and worldwide. These 
tumors can range from low-grade papillary neoplasm to less frequent 
more aggressive and invasive high-grade tumors [1]. More than 
70% of superficial tumors recur, and about one-third of the patients 
have tumor progression, which can affect the quality of their life [2]. 
Treatment failure, recurrence, and metastasis in bladder cancer are 
attributed to a subset of tumor cells expressing cancer stem cell (CSC) 
markers. CSCs have been isolated from leukemia and from a wide 
spectrum of solid tumors, including breast cancer, using putative CSC 
markers such as octamer-binding transcription factor 4 (OCT4), CD133, 
aldehyde dehydrogenase 1, and CD44 [3]. Some unique characteristics 
of CSCs include an increased expression of telomerase and adenosine 
triphosphate-binding cascade transporters and evasion of apoptosis. 
CSCs have become the target in treating various cancers. It has to 
be tested what connections are between CSCs and tumor-initiating 
cells [4]. Characteristic markers and proteins may help to identify 
bladder CSCs and thus early stages of bladder cancer. OCT-4 (the 
gatekeeper of self-renewal), also known as POU domain, class 5, 
transcription factor 1 (POU5F1), is a protein that in humans is encoded 
by the POU5F1 gene [5]. OCT-4 is a homeodomain transcription 
factor of the POU family. It is critically involved in the self-renewal 
of undifferentiated embryonic stem cells. As such, it is frequently 
used as a marker for undifferentiated cells. OCT-4 is a member of the 
octamer transcription factor family, so named because they bind the 
octameric (8-unit) DNA nucleotide sequence ATTTGCAT [6]. The OCT-4 
transcription factor is initially active as a maternal factor in the oocyte 
and remains active in embryos throughout the pre-implantation period. 
OCT-4 can form a heterodimer with SOX2 so that these two proteins 
bind DNA together [7]. Mouse embryos that are OCT-4 deficient or have 
low expression levels of OCT-4 fail to form the inner cell mass, lose 
pluripotency, and differentiate into trophectoderm [8]. Therefore, the 
level of OCT-4 expression in mice is vital for regulating pluripotency 
and early cell differentiation since one of its main functions is to keep 
the embryo from differentiating [9]. In a mature organism, OCT4 is not 
present in mature and differentiated cells and is found only in germ cells. 
OCT4 gene encodes three transcripts and four protein isoforms that are 
generated by alternative splicing, OCT4A, and OCT4B, and OCT4B1. It is 
suggested that OCT4A and OCT4B can be distinguished by their distinct 
subcellular localization [10]. Only the OCT4A form, which is present in 
cell nuclei, exhibits transcription factor functions and is responsible for 
maintaining cells at an undifferentiated stage, stem cell properties, and 
the ability for self-renewal. OCT4 regulates the expression of several 
target genes, including NANOG, SOX-2, REX-1, and CDX-2, involved in 
the regulation of pluripotency. OCT4 is generally considered a universal 
marker of pluripotent stem cells [11]. OCT4 expression in cancer cells: 
The presence of OCT4 protein is associated with, for example, poor 
prognosis in non-small-cell lung cancer, hepatic cancer, and esophageal 
squamous cell carcinoma. One possible mechanism responsible for 
the more aggressive behavior of cancers and worse clinical outcomes 
with cells expressing OCT4 is the presence of the stem cell phenotype 
in cancers related to OCT4-mediated dedifferentiation and related 
chemoresistance [12].
METHODS
A total number of 60 tissue samples were collected for the study, 
30 samples of Group A retrospective obtained from archives of 
histopathology unit with 30 prospective samples were obtained from 
the Directorate of Forensic Medicine at Baghdad Medical City. The 
patients’ medical reports, with full histopathological parameters, were 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.33189
Research Article
314
Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 313-316
 Mohammed and Ahmed 
collected and reviewed. After appropriate trimming, a serial of four 
micrometer-thick tissue sections was obtained using the automated 
microtome. For each case, two sections were taken; the first was placed 
on an ordinary slide and stained with hematoxylin and eosin to confirm 
the diagnosis and to determine the histological type and grade for the 
tumor and the second section was put on the positively charged slides 
for immunohistochemical staining with anti-OCT4 antibody.
Immunohistochemical staining
Slides preparation was placed in semi-vertical position in the oven 
at 65°C overnight. The slides were covered by water until ready to 
perform antigen retrieval; they should be kept wet because it will yield 
a non-specific antibody binding.
•	 Heat-induced	epitope:	Slides	were	put	 in	a	vertical	position	 then	
put in 250 ml (10 mmol sodium citrate buffer complete with wash 
buffer, ph 6) in a plastic container then cover and heated at 95 for 
5 min allow the slides to cool in the buffer for approximately 20 min. 
Wash	in	deionized	H2O 3 times for 2 min each, aspirate excess liquid 
from slides.
•	 Peroxidase	block:	Incubate	for	7–10	min	in	50	ul	hydrogen	peroxide	
in a humid chamber to quench endogenous peroxidase activity. Wash 
in	phosphate-buffered	saline	 (PBS)	 twice	 for	5–7	min	each	 then	
drained.
•	 Protein	 block:	 The	 slides	were	 incubated	with	 protein	 block	
UltraCruz® blocking reagent in a humid chamber for 1 h to eliminate 
non-specific	background	staining	 then	drained	 for	a	 few	seconds	
without a rinse and wipe around with a piece of tissue paper.
•	 Primary	antibody:	50	ul	of	prediluted	primary	antibody	was	placed	
into sections (dilution 1:70 for OCT4) incubated in a wet chamber 
at 4°C overnight for OCT4.
•	 The	slides	were	washed	with	fresh	PBS	twice	for	few	minutes	each.	
Then, the slides were drained.
•	 Conjugated	secondary	antibody	enough	drops	of	secondary	antibody	
were applied to cover the specimen and incubated in a humid 
chamber at room temperature for 60 min. Then, the slides rinse with 
PBS 2 × 5 min then drained and blotted.
•	 Substrate	chromogen	solution:	50	drops	of	diaminobenzidine	(DAB)	
substrate with one drop of chromogen were mixed, few drops were 
added and incubated for 10 min in the humid chamber or until 
desired stain intensity develops, then washed with tap water for few 
minutes each.
•	 Counterstain	with	Mayer’s	hematoxylin	was	used	 for	1	min,	 then	
washed with tap water, followed by distal water for few minutes 
then slides were drained and blotted.
•	 Mounting:	One	to	two	drops	of	mounting	media	are	applied	onto	the	
sections, then covered with coverslips and left to dry overnight.
Evaluation of immunostaining scores
The cells were scored as positive or negative staining depending 
on the presence of distinct brown nuclear staining. The accuracy 
of the positive and strongly positive categories was further tested 
and confirmed by ranking each slide from the lowest to highest 
intensity and extent of staining and location was also revealed for 
each marker. The slides were examined with low-power microscopy 
×10 to determine the regions of highest staining, if they show no 
staining at low power, reexamination was done by high power 
×400 to determine area of weak staining, five fields of each slide 
were examined and scored semi-quantitatively by calculating the 
proportion of positively stained cells over the total number of tumor 
cells examined (%) and samples were graded according to the extent 
of staining and intensity. 
Statistical analysis
The data analyzed using the Statistical Package for the Social Sciences 
version 25. The data presented as mean, standard deviation, and ranges. 
Categorical data presented by frequencies and percentages. Pearson’s 
Chi-square test was used to assess the statistical association between 
different associated variables. A level of p<0.05 was considered 
statistically significant.
RESULTS
In this study, OCT4 was positive in 80% of specimens of Group A and 
3.3% of specimens of Group B. We noticed that the highest proportion 
of patients with positive OCT4 result was diagnosed with TCC (97.6%) 
with a significant association (p=0.001) between OCT4 marker result 
and prevalence of TCC (Table 1).
The association between the OCT4 marker result and certain 
clinicopathological features is shown in Table 2. The highest prevalence 
of positive OCT4 result was found in patients with inflammation and 
necrosis (90.9%) with a significant association (p=0.013) between 
OCT4 result and inflammation with necrosis. Regarding muscular 
invasion, we noticed that 87.5% of patients with muscular invasion 
showed positive OCT4 marker result with a significant association 
(p=0.039) between OCT4 marker result and muscular invasion. There 
was	no	 significant	 association	 (p≥0.05)	between	OCT4	marker	 result	
and other histopathological features of patients in Group A (Fig. 1).
Regarding OCT4 marker, it was highy sensitive and specific 
(sensitivity=80%, specificity=96.6%), (Table 3).
DISCUSSION
OCT4 was positive in 80% of Group A and 3.3% in Group B, in 
concomitant to Chinese study (2007) conducted on 49 bladder cancer 
biopsy samples and found that 40 of 49 bladder cancer samples (81.6%) 
showed the expression of OCT-4 of cancer cells [13]. In comparison to 









Positive 24 (80.0) 1 (3.3) 25 (41.6)
Negative 6 (20.0) 29 (96.7) 35 (58.3)
OCT4: Octamer-binding transcription factor 4, CSC: Cancer stem cell
Figure 1: Histopathological sections of bladder. (a) High-grade 
transitional cell carcinoma (TCC), magnification ×10, (Hematoxylin-
eosin). (b) +ve IHC expression of octamer-binding transcription 
factor 4 (OCT4) marker in high-grade TCC of the bladder, brownish 
discoloration of the nuclear stain, strong intensity, × 40. (c) –ve IHC 
expression of OCT4 marker in high-grade TCC of the bladder, bluish 
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another study conducted in Iran (2007), a higher results observed as 
they detected the expression of OCT4 in almost all 96% of the examined 
tumor samples of bladder (31/32) 33% of Group C samples (3/9 of 
those without carcinoma) (Atlasi et al., 2007), and in Iran 2009, on 
140 patients with bladder carcinoma, as noticed that among 140 cases, 
9 (6%) cases showed no immunoreactivity for the OCT4 protein, 
whereas 131 (94%) cases showed positive immunoreactivity with a 
variety of intensities [14]. Lower results conducted in Egypt at 2017 on 
84 urothelial tumor specimens, and found, of all the tumor specimens, 
30 (35.8%) cases showed tumor positivity, whereas 54 (64.2%) cases 
were negative for OCT4 staining, in which all positive results found 
in high-grade urothelial tumor specimens [15]. The most reasonable 
explanation for this discrepancy in results was probably the different 
representation of different grade specimens in each study.
Our results also showed that there was a significant association 
between the OCT4 positive result and inflammation with necrosis 
(p=0.013) in 90.9% of patients in Group A. Furthermore, with 
muscular invasion, it significantly related (p=0.039, 87.5%) 
of	 patients	 and	 no	 significant	 association	 (p≥0.05)	 with	 other	
clinicopathological features. Similarly, a study conducted in Japan 
(2011) showed that the immunohistochemical analysis demonstrated 
that the positive rate of OCT4 expression was significantly associated 
with higher grade cancer (G2 and G3) in comparison with that of 
the lower grade (G1) [16]. Furthermore, in Iran (2017), researchers 
found that there was a significant correlation between the expression 
of OCT4 and the tumor stage (p<0.001), indicating a higher level of 
expression in higher stage tumors and a significant correlation was 
also observed between the OCT4 intensity with muscular invasion 
(p=0.02) but differ in that no correlation with grade of tumor 
(Sedaghat et al., 2017). In Egypt (2016), researchers noticed that a 
significant association between OCT4 expression and tumor grade 
(p=0.003), tumor morphology (p<0.001), tumor stage (p<0.001), 
and progression of the tumor from non-muscle invasive to invasive 
urothelial carcinoma (p=0.001) (Asar et al., 2017).
Differently, Iranian researchers notice that the sensitivity and 
specificity of OCT4 expression as a molecular marker in the detection 
of bladder tumors were determined as 96 and 66%, respectively, in a 
study conducted in 2007 (Atlasi et al., 2007).
CONCLUSION
There was a significant expression of OCT4 in high-grade TCC; OCT4 
can be considered as a key regulator of tumor progression, aggressive 
behavior, and metastasis. Furthermore, it is a reliable marker for the 
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